BridgeBio Oncology Therapeutics, Inc. (BBOT)vsRevolution Medicines Inc (RVMD)
BBOT
BridgeBio Oncology Therapeutics, Inc.
$3.89
-1.27%
HEALTHCARE · Cap: $319.89M
RVMD
Revolution Medicines Inc
$206.64
+0.36%
HEALTHCARE · Cap: $44.29B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. BBOT earns a higher WallStSmart Score of 31/100 (F).
BBOT
Avoid31
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 17.0x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : BBOT
The strongest argument for BBOT centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : BBOT
The primary concerns for BBOT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
BBOT is growing revenue faster at 0.0% — sustainability is the question.
BBOT generates stronger free cash flow (-44M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BBOT scores higher overall (31/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BridgeBio Oncology Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients. The company is headquartered in South San Francisco, California.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?